SUMMARY Cerebral blood flow (CBF) has been measured using a non-invasive Xenon'33 clearance technique in six normal subjects after 2 days pretreatment with oral indomethacin at a dose of 100 mg/day. The results were compared with placebo given in a double blind balanced cross-over design. Indomethacin was found to result in a reduction in resting CBF of about 25% but the reactivity of the cerebrovascular circulation to carbon dioxide was preserved at normal levels. Infusions of epoprostenol (prostacyclin, PGI2) at a dose of 5 ng/kg/min resulted in a reduction of CBF of about 10% after placebo but no significant change in CBF after indomethacin. The results suggest that prostaglandins are involved in the maintenance of cerebrovascular tone but not in the mechanism of cerebral vasodilation accompanying hypercapnia. The combination of indomethacin and PGI2 has been proposed as a treatment of cerebral artery spasm and the findings suggest that the combination therapy would not be accompanied by undesirable intracerebral steal.
There is considerable evidence, recently reviewed by Pickard,' which suggests that prostaglandins and particularly prostacyclin (epoprostenol, PGI2) are involved in the control of cerebral blood flow (CBF). The evidence comes from two separate lines, firstly experiments on the effects of indomethacin used as an inhibitor of prostaglandin synthesis, and secondly animal experiments on the direct effects of PGI, both in vitro and in vivo. Pickard and Mackenzie2 first showed that in baboons intraarterial indomethacin reduced resting CBF, and almost abolished the rise in CBF that normally results from hypercapnia. Similar findings were recently reported in humans studied 1 hour after rectal indomethacin.3 These results were taken as evidence that some endogenous prostaglandin was involved in the CBF response to hypercpania and from the very rapid onset of the effect of indomethacin it was concluded that a prostaglandin with a very rapid turnover was involved in CBF regulation. Prostacyclin (epoprostenol, PGI2) appeared to have the required characteristics. It is formed by vascular endothelium4 and can be produced in vitro by cerebral vessels.5 6 Blood pressure was recorded from the left arm with a standard mercury sphygmomanometer and the pulse rate measured over 30 seconds from the radial pulse on three occasions during the CBF measurement. Arterial partial pressure of carbon dioxide (pCO2) was estimated by monitoring expiratory CO concentration with a Datex CD 300 infra red analyser. The pCO2 levels were calculated from the mean end tidal concentration over the first 5 minutes of each study. Samples were taken for estimation of indomethacin blood levels at the start of the first and third CBF estimations on each study day, and were analysed by a modification of the spectrofluorometric method of Hucker.'7
Results
The CBF results are shown in the table. Baseline resting CBF was found to be reduced by about 25 % following indomethacin pretreatment compared to placebo (p < 0-02). These results and the response to hypercapnia are illustrated in the figure. Hypercapnia caused a significant rise in CBF (p < 0.01) both after indomethacin and placebo pretreatments but there was no significant difference in the responses with the two pretreatments. The mean % reactivity to CO2 (% rise in CBF with each kPa rise in pCO2) was 34-7 on placebo and 33-7 on indomethacin.
The infusion of PGI2 resulted in a small reduction in CBF of about 10% following placebo treatment compared to the baseline levels (p < 0.05). In contrast, following indomethacin treatment there was no significant change in CBF. There was no significant difference in the pCO2 measurements between indomethacin and placebo pretreatment either during the resting measurement or after PGI,. The patterns of end-tidal Xe'33 concentration were not significantly altered by the PGI2 infusions and it is therefore unlikely that there were significant alterations in the ratio of arterial to expired Xe'33 concentrations that might have influenced the accuracy of the correction for arterial recirculation.
Indomethacin produced no significant differences in heart rate or blood pressure compared to placebo at normocapnia, hypercapnia or during PGI . However, within each treatment group, PGI2 infusion caused a small rise in heart rate, mean increase 9*4 beats/min on placebo, 6-8 on indomethacin (p < 0.05 cf baseline). There was no significant change in systolic blood pressure during PGI2, but diastolic Effect of indomethacin on cerebral blood flow and carbon dioxide reactivity The current study has also demonstrated that pretreatment with oral indomethacin does not alter the normal cerebrovascular response to an increase in arterial pCO2. This is in contrast to the conclusions of two previous studies, which have suggested that indomethacin reduces cerebral vasodilation during hypercapnia in man3 and the baboon.2 However, both these studies examined the effects of acute administration of indomethacin, rather than two days pretreatment, and this may explain the results. There are also other methodological differences between the studies which may be relevant. The ! flow normal CBF response to an increase in arterial wans ± SEM.
Pickles, Brown, Thomas The finding that PGI2 reduces CBF slightly after placebo pretreatment in normal individuals confirms previous studies. 14 23 Exogenous PGI2 greatly reduces peripheral resistance' and there is considerable shunting of blood through the GI tract.242S The increase in cardiac output' does not match this fully, and a small drop in blood pressure usually results, which could result in reduced CBF. However, the cerebral circulation is normally protected by the process of autoregulation from fluctuations in perfusion pressure and we have therefore previously suggested'4 that PGI2 may result in a disturbance of autoregulation. However, the finding that CBF remained unchanged and if anything rose in response to PGI2 infusion after indomethacin pretreatment despite equivalent falls in blood pressure makes this suggestion less likely. Taken together the results suggest that exogenous PGI2 has a direct effect on cerebrovascular tone which is dependent on the overall level of other prostaglandins.
Although PGI2 in doses acceptable to conscious humans does not appear to increase the normal level of CBF this does not exclude a therapeutic vasodilator role in pathological areas of the circulation. PGI2 is able to overcome cerebral artery spasm in vitro-'9 and in vivo'°and may therefore have a place in the treatment of subarachnoid haemorrhage. In dogs modest doses of PGI, increase CBF to ischaemic areas of brain only after indomethacin pretreatment." The current studies have shown that combined treatment with PGI2 and indomethacin in patients with cerebrovascular disease would not result in significant vasodilation in normal areas of the brain and would therefore be unlikely to cause undesirable intra cerebral steal of blood away from ischaemic to normal areas.
